Biotech startups in Nanjing, China
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Weikaier Pharmaceutical Technology | Nanjing | Series C | $29.6M | 2026-06-02 |
| IMPACT Therapeutics | Nanjing | Series D | $34.6M | 2024-11-15 |
| Zenshine Pharma | Nanjing | Series C | $13.7M | 2023-10-13 |
| Wimi bio | Nanjing | Series A | $14.1M | 2024-09-19 |
4 rows of the CSV in 5 of its 18 columns.
- The 70 biotech startups in Nanjing, China have raised $1.1B in total.
- 11 of them closed their most recent round in the last 12 months, $84.5M combined.
- The largest of those rounds is Weikaier Pharmaceutical Technology's $29.6M Series C, dated June 2026.
- The most recent is NNB Nutrition's $29.5M Series C on 13 July 2026.
- Health care is the most common other sector, with 59 companies (84%).
- 23% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (27% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
4 of 70| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
| IMPACT Therapeutics | IMPACT Therapeutics develops similar drugs to treat cancer. | Biotech | Series D | $34.6M | 2024-11-15 | BioVenture, Lilly Asia Ventures, Decheng Capital +2 | 51 to 100 | 2009 | |
| Wimi bio | Wimi Bio researches and develops gene editing and biological breeding technologies as a high-tech enterprise. | Biotech | Series A | $14.1M | 2024-09-19 | HosenCare Brothers | 51 to 100 | 2017 | |
| Zenshine Pharma | Zenshine Pharma develops small molecule drugs for cancer and autoimmune diseases. | Biotech | Series C | $13.7M | 2023-10-13 | $28.7M | Matrix Partners China, Cybernaut Venture Capital, Kunlun Capital +2 | 11 to 50 | 2018 |
Table 1. Biotech startups in Nanjing, China: the 4 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 70.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Weikaier Pharmaceutical Technology | Weikaier Pharmaceutical Technology conducts drug research, transfers generic drug technology, and produces and sells pharmaceuticals. | Biotech | Series C | $29.6M | 2026-06-02 | $120.4M | SDIC Venture Capital, Dyee Capital, Nanjing Innovation Capital Group +1 | 501 to 1,000 | 2010 |
Table 2. Biotech startups in Nanjing, China: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | SDIC Venture Capital | Venture capital firm | Xicheng, China | 1 | 1% | 1 | Weikaier Pharmaceutical Technology |
| 2 | Nanjing Innovation Capital Group | Venture capital firm | Nanjing, China | 1 | 1% | 1 | Weikaier Pharmaceutical Technology |
| 3 | Dyee Capital | Private equity firm | Xiamen, China | 1 | 1% | 1 | Weikaier Pharmaceutical Technology |
| 4 | China Life Private Equity Investment | Private equity firm | Beijing, China | 1 | 1% | 1 | Weikaier Pharmaceutical Technology |
| 5 | WuXi Healthcare Ventures | Venture capital firm | Cambridge, United States | 1 | 1% | ||
| 6 | Guangzhou Yuexiu Industrial Investment Fund | Corporate venture arm | Guangzhou, China | 1 | 1% | ||
| 7 | Lilly Asia Ventures | Venture capital firm | Shanghai, China | 1 | 1% | ||
| 8 | BioVenture | Venture capital firm | Suzhou, China | 1 | 1% | ||
| 9 | Decheng Capital | Venture capital firm | Menlo Park, United States | 1 | 1% | ||
| 10 | Matrix Partners China | Venture capital firm | Beijing, China | 1 | 1% | ||
| 11 | Summit Capital | Family office | Seattle, United States | 1 | 1% | ||
| 12 | Hankang Capital | Venture capital firm | Shanghai, China | 1 | 1% | ||
| 13 | Kunlun Capital | Venture capital firm | Beijing, China | 1 | 1% | ||
| 14 | Cybernaut Venture Capital | Private equity firm | Hangzhou, China | 1 | 1% | ||
| 15 | HosenCare Brothers | Venture capital firm | Beijing, China | 1 | 1% |
Table 3. Biotech startups in Nanjing, China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 59 | 84% | $1.1B |
| Artificial intelligence | 1 | 1% | |
| Software | 1 | 1% |
Table 4. Biotech startups in Nanjing, China by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Seed | 15 | 21% | $789K |
| Series A | 26 | 37% | $14.1M |
| Series B | 11 | 16% | $14.0M |
| Series C | 15 | 21% | $29.6M |
| Series D+ | 3 | 4% | $25.0M |
Table 5. Biotech startups in Nanjing, China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| October 2026 | 3 | 27% | |
| July 2026 | 1 | 9% | $29.5M |
| June 2026 | 1 | 9% | $29.6M |
| May 2026 | 1 | 9% | |
| January 2026 | 2 | 18% | $483K |
| December 2025 | 1 | 9% | $25.0M |
| November 2025 | 2 | 18% |
Table 6. Biotech startups in Nanjing, China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 8 | 11% | $59.5M |
| 2025 | 14 | 20% | $99.7M |
| 2024 | 5 | 7% | $78.9M |
| 2023 | 14 | 20% | $70.0M |
| 2022 | 8 | 11% | $107.3M |
| 2021 | 6 | 9% | $325.2M |
Table 7. Biotech startups in Nanjing, China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 3 | 4% |
| 2020 to 2022 | 13 | 19% |
| 2015 to 2019 | 34 | 49% |
| 2010 to 2014 | 13 | 19% |
| Before 2010 | 7 | 10% |
Table 8. Biotech startups in Nanjing, China by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 4 | 7% |
| 11 to 50 | 15 | 27% |
| 51 to 100 | 14 | 25% |
| 101 to 250 | 7 | 12% |
| 251 to 500 | 5 | 9% |
| 501 to 1,000 | 7 | 12% |
| 1,001 to 5,000 | 4 | 7% |
Table 9. Biotech startups in Nanjing, China by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Nanjing, China. On 16 November 2026 that is 70 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 4 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 70 rows: 28 have no round amount, 0 no city and 28 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Nanjing, China are on the list?
- 70, in the file dated 16 November 2026. 11 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 70 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.